Table 3.
Renal outcomes and death by ACE/ID genotype in the losartan group compared with the placebo group
| Losartan, n/N (%) | Placebo, n/N (%) | Adjusteda Risk Reduction Losartan vs Placebo(95% CI) | Pb | |||||
|---|---|---|---|---|---|---|---|---|
| Composite endpoint of doubling of serum creatinine, ESRD, or death | ||||||||
| II | 72/170 (42.4) | 85/200 (42.5) | 5.8 (−23.3 to 28.0) | 0.215 | ||||
| ID | 155/352 (44.0) | 151/317 (47.6) | 17.6 (3.8 to 29.4) | |||||
| DD | 81/189 (42.9) | 106/207 (51.2) | 27.9 (7.0 to 44.1) | |||||
| ESRD or death | ||||||||
| II | 58/170 (34.1) | 67/200 (33.5) | 7.5 (−24.6 to 31.4) | 0.149 | ||||
| ID | 120/352 (34.1) | 132/317 (41.6) | 22.3 (7.6 to 34.6) | |||||
| DD | 60/189 (31.7) | 87/207 (42.0) | 34.6 (13.0 to 50.9) | |||||
| Doubling of serum creatinine | ||||||||
| II | 40/170 (23.5) | 54/200 (27.0) | 10.2 (−29.2 to 37.6) | 0.250 | ||||
| ID | 77/352 (21.9) | 71/317 (22.4) | 24.3 (6.2 to 38.9) | |||||
| DD | 38/189 (20.1) | 60/207 (29.0) | 36.2 (8.5 to 55.5) | |||||
| ESRD | ||||||||
| II | 39/170 (22.9) | 42/200 (21.0) | 3.1 (−41.0 to 33.3) | 0.032 | ||||
| ID | 67/352 (19.0) | 84/317 (26.5) | 30.5 (13.0 to 44.4) | |||||
| DD | 30/189 (15.9) | 56/207 (27.1) | 50.1 (27.1 to 65.8) | |||||
| Death | ||||||||
| II | 28/170 (16.5) | 37/200 (18.5) | 0.4 (−49.2 to 33.5) | 0.927 | ||||
| ID | 82/352 (23.3) | 64/317 (20.2) | 1.8 (−23.4 to 21.9) | |||||
| DD | 38/189 (20.1) | 49/207 (23.7) | 3.2 (−39.9 to 33.1) | |||||
| Doubling of serum creatinine or ESRD | ||||||||
| II | 56/170 (32.9) | 65/200 (32.5) | 2.3 (−33.7 to 28.6) | 0.084 | ||||
| ID | 105/352 (29.8) | 104/317 (32.8) | 21.6 (5.8 to 34.8) | |||||
| DD | 52/189 (27.5) | 79/207 (38.2) | 37.1 (14.4 to 53.8) | |||||
CI, confidence interval; ESRD, end-stage renal disease; n/N, number of patients who had an event/total number of patients.
a
Adjusted with terms including treatment (losartan or placebo), geographic region, genotype, and the treatment × genotype interaction.
b
P value for treatment × genotype interaction (i.e., comparison of the losartan treatment effect between the 3 genotype groups).